The proposed study is a phase II randomized trial testing an innovative concept of comparing local therapy to systemic therapy, e.g. pazopanib, in patients with newly diagnosed limited metastatic RCC. We hypothesize that local therapy can prolong progression-free survival for patients with limited metastasis, and delaying the initiation of systemic therapy does not adversely affect survival. Patient will be stratified by Heng's criteria. Patients that are curable by metastatectomy as well as patients with poor prognosis and high chance of disease dissemination according to the prognostic factors will be excluded.